Japan Gene Synthesis Research Use Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Japan Gene Synthesis Research Use Market Overview

• The Japan Gene Synthesis Research Use Market is valued at USD 180 million, based on a five-year historical analysis of the broader gene synthesis and DNA synthesis markets in the country. This growth is primarily driven by advancements in biotechnology, increasing investments in genomic research, and the rising demand for synthetic biology applications. The market is further supported by the growing prevalence of chronic and rare diseases, the aging population, and the need for personalized medicine, which has led to a surge in research activities across pharmaceutical, biotechnology, and academic sectors.
• Key regional hubs in this market include Tokyo and the greater Kanto region, along with the Kansai region (Osaka–Kyoto–Kobe), which dominate due to their robust research infrastructure, presence of leading academic institutions such as the University of Tokyo, Kyoto University, and RIKEN institutes, and a high concentration of biotechnology and pharmaceutical companies. These regions operate as major centers for innovation and collaboration, with dedicated initiatives such as the Kanto life science clusters and the Kansai “BioCluster” helping create an environment conducive to advancements in gene synthesis technologies and applications.
• Japan’s policy environment for genomics and synthetic biology research is supported by national strategies and funding programs under initiatives such as Society 5.0 and large-scale projects led by agencies including the Japan Agency for Medical Research and Development (AMED) and RIKEN, which channel substantial funding into genome and gene synthesis–related R&D. A key binding instrument is the Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) issued by the Government of Japan, which sets requirements for risk classification, review by certified special committees, and facility/physician approval for clinical use of processed cells, thereby shaping standards and compliance expectations for gene and cell therapy–oriented research that heavily relies on gene synthesis technologies.

Japan Gene Synthesis Research Use Market Segmentation

By Service Type:The service type segmentation includes various methods of gene synthesis, each catering to specific research needs. The dominant subsegment is Full-length Gene Synthesis, which is preferred for its comprehensive approach to gene construction, allowing researchers to create entire genes for various applications such as gene and cell therapy constructs, expression systems, and functional genomics studies. Gene Fragment Synthesis also holds a significant share, as it is widely used for cloning, modular assembly, mutagenesis, and high-throughput screening. The demand for Custom Vector and Plasmid Construction is increasing due to the rise in synthetic biology, CRISPR-based genome editing, and viral vector production, where tailored plasmids and expression cassettes are required for precise and efficient experimentation.

By Application:The application segmentation encompasses various fields where gene synthesis is utilized. The leading subsegment is Gene and Cell Therapy Research, driven by the increasing focus on personalized medicine, regenerative therapies, and Japan’s progressive framework for regenerative medicine and advanced therapies, which encourages translational research using synthetic genes and vectors. Vaccine and Viral Vector Research is also significant, especially following recent global health challenges and Japan’s drive to strengthen domestic vaccine and mRNA/viral vector manufacturing capabilities, which rely on viral DNA and plasmid design. The rise of CRISPR and Genome Editing Research has further propelled the demand for gene synthesis services, as researchers seek precise genetic modifications, custom guide RNA cassettes, and donor templates to support disease models, functional genomics, and agricultural biotechnology applications.

Japan Gene Synthesis Research Use Market Competitive Landscape

The Japan Gene Synthesis Research Use Market is characterized by a dynamic mix of regional and international players. Leading participants such as Eurofins Genomics Japan, GenScript, Thermo Fisher Scientific, Integrated DNA Technologies (IDT), Twist Bioscience, BIONEER Corporation, Azenta Life Sciences, Merck KGaA (MilliporeSigma / Sigma-Aldrich), Takara Bio Inc., FASMAC Co., Ltd., DNA Script, Brooks / Azenta Genomics (GENEWIZ), OriGene Technologies, Codex DNA (Telesis Bio), Other Emerging Japanese Gene Synthesis Providers contribute to innovation, geographic expansion, and service delivery in this space.

Japan Gene Synthesis Research Use Market Industry Analysis

Growth Drivers

• Increasing Demand for Synthetic Biology Applications:The synthetic biology market in Japan is projected to reach ¥1.2 trillion in future, driven by applications in healthcare, agriculture, and environmental management. The rise in biopharmaceuticals, particularly in gene therapies, is a significant contributor, with the biopharmaceutical sector expected to grow by ¥300 billion. This demand is fueled by advancements in technology and the need for innovative solutions to complex biological problems.
• Advancements in Gene Editing Technologies:The CRISPR technology market in Japan is anticipated to grow to ¥50 billion in future, reflecting the rapid advancements in gene editing. These technologies enable precise modifications in genetic material, enhancing research capabilities. The increasing number of research publications, which reached over 10,000 in future, indicates a robust interest in gene editing, further driving the demand for gene synthesis services in various sectors.
• Rising Investment in Biotechnology Research:Japan's biotechnology sector received approximately ¥200 billion in funding in future, with a projected increase to ¥250 billion in future. This investment is crucial for developing innovative gene synthesis technologies and applications. The government’s commitment to biotechnology, reflected in initiatives like the "Biotechnology Strategy," aims to enhance Japan's global competitiveness, thereby boosting the gene synthesis market significantly.

Market Challenges

• High Costs Associated with Gene Synthesis:The average cost of gene synthesis in Japan is around ¥100,000 per gene, which poses a barrier for many research institutions and startups. This high cost limits accessibility, particularly for smaller entities that may lack sufficient funding. As a result, the market faces challenges in expanding its user base, which is critical for long-term growth and innovation in gene synthesis applications.
• Regulatory Hurdles in Genetic Research:Japan's regulatory framework for genetic research is complex, with stringent guidelines that can delay project timelines. The approval process for new genetic technologies can take up to 18 months, hindering innovation. Additionally, compliance with international standards adds layers of complexity, making it challenging for companies to navigate the regulatory landscape effectively, which can stifle market growth.

Japan Gene Synthesis Research Use Market Future Outlook

The future of the gene synthesis market in Japan appears promising, driven by technological advancements and increasing applications across various sectors. The integration of artificial intelligence in genetic research is expected to enhance efficiency and accuracy, while the shift towards automation will streamline processes. Furthermore, the growing emphasis on sustainable practices in biotechnology will likely lead to innovative solutions that address environmental challenges, positioning Japan as a leader in the global gene synthesis landscape.

Market Opportunities

• Expansion of Research Institutions:The establishment of new research institutions in Japan, projected to increase by 15% in future, presents significant opportunities for gene synthesis services. These institutions will require advanced gene synthesis capabilities to support their research initiatives, thereby driving demand and fostering collaboration within the biotechnology sector.
• Collaborations with Pharmaceutical Companies:Strategic partnerships between gene synthesis firms and pharmaceutical companies are expected to grow, with an estimated 20 new collaborations in future. These partnerships will facilitate the development of novel therapies and enhance the application of gene synthesis in drug discovery, creating a robust ecosystem that benefits both sectors.